BBLG Bone Biologics Corp

Nasdaq bonebiologics.com


$ 2.66 $ 0.13 (5.06 %)    

Wednesday, 15-Oct-2025 12:30:29 EDT
QQQ $ 602.51 $ -1.31 (-0.22 %)
DIA $ 463.42 $ -1.22 (-0.26 %)
SPY $ 664.96 $ -1.82 (-0.27 %)
TLT $ 90.68 $ -0.27 (-0.3 %)
GLD $ 385.85 $ -0.11 (-0.03 %)
$ 2.57
$ 2.61
$ 2.62 x 100
$ 2.71 x 228
$ 2.61 - $ 2.75
$ 1.95 - $ 13.80
27,867
na
548,640
$ 2.17
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 02-26-2025 01-01-1970 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-09-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 02-21-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-30-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-13-2022 03-31-2022 10-Q
15 03-15-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
18 05-21-2021 03-31-2021 10-Q
19 04-15-2021 03-31-2020 10-Q
20 04-15-2021 06-30-2020 10-Q
21 04-15-2021 09-30-2020 10-Q
22 04-15-2021 12-31-2020 10-K
23 03-30-2020 12-31-2019 10-K
24 11-14-2019 09-30-2019 10-Q
25 08-14-2019 06-30-2019 10-Q
26 05-14-2019 03-31-2019 10-Q
27 03-29-2019 12-31-2018 10-K
28 11-16-2018 09-30-2018 10-Q
29 08-14-2018 06-30-2018 10-Q
30 05-15-2018 03-31-2018 10-Q
31 04-02-2018 12-31-2017 10-K
32 11-14-2017 09-30-2017 10-Q
33 08-08-2017 06-30-2017 10-Q
34 05-12-2017 03-31-2017 10-Q
35 03-30-2017 12-31-2016 10-K
36 11-14-2016 09-30-2016 10-Q
37 08-15-2016 06-30-2016 10-Q
38 05-13-2016 03-31-2016 10-Q
39 03-28-2016 12-31-2015 10-K
40 11-16-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 bone-biologics-ceo-issues-stockholder-letter-highlighting-nb1-clinical-progress-product-improvements-year-end-enrollment-goal-expanded-shelf-life-interim-trial-update-and-2026-financial-outlook

One-Year OutlookThe firm expect to achieve a number of value-creating events in the coming year under our cost-efficient busine...

 bone-biologics-q2-eps-133-misses-058-estimate

Bone Biologics (NASDAQ:BBLG) reported quarterly losses of $(1.33) per share which missed the analyst consensus estimate of $(0....

 why-is-bone-biologics-stock-surging-on-friday

Bone Biologics filed a USPTO patent for NELL-1 and announced a $5 million offering to support trials and expand its bone regene...

Core News & Articles

Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiol...

Core News & Articles
Market-Moving News for June 27th
06/27/2025 11:22:38

NKE: 11% | Nike Q4 Earnings: Revenue Beat, EPS Beat, Headwinds Expected To Moderate Moving Forward, Company Playing 'Sport ...

 bone-biologics-corp-for-mixed-shelf-of-up-to-35m

– SEC Filing

 bone-biologics-approves-plan-amendment-to-increase-shares-by-30m

-SEC Filing

 watching-bone-biologics-zacks-small-cap-research-gives-stock-1650-price-valuation

https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_05132025_BBLG_Sorensen.pdf

 bone-biologics-q1-eps-032-beats-048-estimate

Bone Biologics (NASDAQ:BBLG) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.48...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION